Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) have been assigned an average rating of “Moderate Buy” from the nine research firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $6.57.

Several brokerages have weighed in on NMRA. HC Wainwright reissued a “buy” rating on shares of Neumora Therapeutics in a research note on Tuesday, July 28th. Wall Street Zen raised Neumora Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. Needham & Company LLC dropped their target price on Neumora Therapeutics from $8.00 to $5.00 and set a “buy” rating for the company in a report on Tuesday, June 16th. Weiss Ratings downgraded Neumora Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 14th. Finally, Royal Bank Of Canada decreased their price target on Neumora Therapeutics from $7.00 to $5.00 and set an “outperform” rating on the stock in a report on Monday, July 13th.

Neumora Therapeutics Stock Performance

Neumora Therapeutics stock opened at $0.68 on Friday. The company’s 50-day moving average price is $1.37 and its 200-day moving average price is $1.77. Neumora Therapeutics has a twelve month low of $0.63 and a twelve month high of $3.65. The company has a quick ratio of 4.50, a current ratio of 4.50 and a debt-to-equity ratio of 1.19. The company has a market cap of $127.32 million, a PE ratio of -0.55 and a beta of 2.71.

Neumora Therapeutics (NASDAQ:NMRA) last announced its earnings results on Friday, August 14th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.01. On average, equities research analysts forecast that Neumora Therapeutics will post -0.85 EPS for the current fiscal year.

Insider Buying and Selling

In other Neumora Therapeutics news, insider Daljit Singh Aurora sold 91,690 shares of the business’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1.50, for a total transaction of $137,535.00. Following the transaction, the insider owned 48,750 shares in the company, valued at $73,125. The trade was a 65.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders have sold 453,833 shares of company stock worth $701,219 over the last ninety days. 26.94% of the stock is owned by insiders.

Institutional Investors Weigh In On Neumora Therapeutics

Several institutional investors have recently made changes to their positions in the company. BlackRock Inc. bought a new position in Neumora Therapeutics during the 2nd quarter valued at about $13,246,000. Johnson & Johnson bought a new stake in Neumora Therapeutics in the second quarter worth about $3,144,057. Perceptive Advisors LLC bought a new position in shares of Neumora Therapeutics during the first quarter valued at approximately $9,953,000. ICONIQ Capital LLC purchased a new position in Neumora Therapeutics in the 2nd quarter worth about $4,350,000. Finally, Siren L.L.C. lifted its holdings in Neumora Therapeutics by 35.1% during the 1st quarter. Siren L.L.C. now owns 8,497,822 shares of the company’s stock valued at $16,571,000 after buying an additional 2,209,039 shares in the last quarter. Institutional investors own 47.65% of the company’s stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and neuropsychiatric disorders. The company combines neuroscience research with data science and computational tools to identify disease mechanisms, discover potential drug targets and support the development of precision medicines for conditions affecting the brain.

Neumora’s pipeline includes navacaprant, an investigational selective kappa opioid receptor antagonist being developed for major depressive disorder.